Efficacy and safety of fractional 1064-nm picosecond laser on skin quality

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230516009

Enrollment

Registered

2023-05-16

Start date

2023-05-15

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient with mild to moderate wrinkle fractional 1064-nm picosecond laser,skin quality

Interventions

Patient were treated with fractional 1064-nm picosecond laser 2 sessions every 4 weeks. Then they were instructed to follow up at 1, 3, and 6 months after the treatment

Experimental Device

fractional 1064-nm picosecond laser

Eligibility

Sex/Gender

All

Age

35 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Aged 35-45 years 2. Mild to moderate wrinkle and skin laxity

Exclusion criteria

Exclusion criteria: 1. Patients who are pregnant and lactating 2. Patients had history of anesthesia drug allergy 3. Patients with other skin disease, or having infection at the area of face 4. Immunocompromised patients 5. Patients with hypertrophic scar or keloid 6. Patients with history of Cushing syndrome or Ehlers-Danlos syndromd 7.Patients with cancers or skin cancers 8.Patients with mental disorders 9.Patiens with botox or filler of energy-based deviced within 6 month before joining research 10. patient with keloid or hypertrophic scar

Design outcomes

Primary

Measure	Time frame
Skin wrinkle and texture Baseline, 4 weeks, 8 weeks, 16 weeks, 28 weeks Antera	—

Secondary

Measure	Time frame
Skin elasticity Baseline, 4 weeks, 8 weeks, 16 weeks, 28 weeks Cutometer,Skin hydration Baseline, 4 weeks, 8 weeks, 16 weeks, 28 weeks corneometer,Melanin and erythema index Baseline, 4 weeks, 8 weeks, 16 weeks, 28 weeks mexameter,Sebum level Baseline, 4 weeks, 8 weeks, 16 weeks, 28 weeks sebumeter,pain score Baseline, 4 weeks, 8 weeks, 16 weeks, 28 weeks Visual Analog Scale,Physician improvement assessment Baseline, 4 weeks, 8 weeks, 16 weeks, 28 weeks Quatile scale,Patient improvement assessment Baseline, 4 weeks, 8 weeks, 16 weeks, 28 weeks Quatile scale,Safety Baseline, 4 weeks, 8 weeks, 16 weeks, 28 weeks Adverse events	—

Measure

Time frame

Skin elasticity Baseline, 4 weeks, 8 weeks, 16 weeks, 28 weeks Cutometer,Skin hydration Baseline, 4 weeks, 8 weeks, 16 weeks, 28 weeks corneometer,Melanin and erythema index Baseline, 4 weeks, 8 weeks, 16 weeks, 28 weeks mexameter,Sebum level Baseline, 4 weeks, 8 weeks, 16 weeks, 28 weeks sebumeter,pain score Baseline, 4 weeks, 8 weeks, 16 weeks, 28 weeks Visual Analog Scale,Physician improvement assessment Baseline, 4 weeks, 8 weeks, 16 weeks, 28 weeks Quatile scale,Patient improvement assessment Baseline, 4 weeks, 8 weeks, 16 weeks, 28 weeks Quatile scale,Safety Baseline, 4 weeks, 8 weeks, 16 weeks, 28 weeks Adverse events

—

Countries

Thailand

Contacts

Public ContactWoraphong Manuskiatti

Faculty of Medicine Siriraj Hospital, Mahidol University.

woraphong.man@mahidol.ac.th664194333

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026